Oncotelic Therapeutics, Inc.

OTCPK:OTLC Stock Report

Market Cap: US$12.7m

Oncotelic Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Vuong Trieu

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure11.1yrs
CEO ownership24.6%
Management average tenure5.3yrs
Board average tenureno data

Recent management updates

Recent updates

CEO Compensation Analysis

How has Vuong Trieu's remuneration changed compared to Oncotelic Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$5m

Jun 30 2024n/an/a

-US$1m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023n/an/a

-US$8m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$13m

Mar 31 2023n/an/a

US$9m

Dec 31 2022US$129kUS$38k

US$5m

Sep 30 2022n/an/a

US$9m

Jun 30 2022n/an/a

US$8m

Mar 31 2022n/an/a

-US$11m

Dec 31 2021US$257kUS$190k

-US$9m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$216kUS$169k

-US$10m

Sep 30 2020n/an/a

-US$10m

Jun 30 2020n/an/a

-US$9m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019US$259kUS$115k

-US$7m

Compensation vs Market: Insufficient data to establish whether Vuong's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Vuong's compensation has been consistent with company performance over the past year.

CEO

Vuong Trieu (61 yo)

11.1yrs

Tenure

Dr. Vuong Trieu, Ph.D. serves as the co-founder, President, Chairman and Chief Executive Officer of Oncotelic Inc. Dr. Trieu serves as Chairman and Chief Executive Officer of Oncotelic Therapeutics, Inc (f...

Leadership Team

NamePositionTenureCompensationOwnership
Vuong Trieu
Chairman & CEO11.1yrsno data24.57%
$ 3.1m
Amit Shah
Chief Financial Officer5.6yrsno data0.088%
$ 11.2k
Anthony Maida
Chief Medical Officer – Translation Medicine & Director4.8yrsno data0.28%
$ 35.5k
Saranjit Saund
CBO & GM of AI Division5.3yrsno data4.04%
$ 513.4k
Steven King
Consultant & Directorno datano data0%
$ 0
Larn Hwang
Chief Scientific Officerno datano data5.76%
$ 731.8k
Seymour Fein
Chief Regulatory Officer & Chief Medical Officer2.8yrsno datano data
Burcak Beser
CTO of AI Divisionno datano datano data

5.3yrs

Average Tenure

61yo

Average Age

Experienced Management: OTLC's management team is seasoned and experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 11:22
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oncotelic Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Theodore O'NeillLitchfield Hills Research, LLC